Equities Analysts Issue Forecasts for Kintara Therapeutics, Inc.’s Q2 2021 Earnings (NASDAQ:KTRA)

Kintara Therapeutics, Inc. (NASDAQ:KTRA) – Investment analysts at Zacks Investment Research issued their Q2 2021 EPS estimates for Kintara Therapeutics in a research report issued to clients and investors on Wednesday, November 18th. Zacks Investment Research analyst J. Vandermosten anticipates that the company will earn ($0.22) per share for the quarter. Zacks Investment Research also issued estimates for Kintara Therapeutics’ Q3 2021 earnings at ($0.21) EPS, Q4 2021 earnings at ($0.15) EPS, FY2021 earnings at ($0.60) EPS and FY2023 earnings at ($0.48) EPS.

Separately, Aegis reaffirmed a “buy” rating and issued a $6.00 price target on shares of Kintara Therapeutics in a research note on Thursday, October 1st.

Shares of Kintara Therapeutics stock opened at $1.45 on Friday. The stock has a 50 day moving average of $1.48. The stock has a market cap of $35.76 million, a PE ratio of -1.65 and a beta of 1.82. Kintara Therapeutics has a one year low of $0.38 and a one year high of $1.95.

Kintara Therapeutics (NASDAQ:KTRA) last announced its quarterly earnings results on Monday, September 21st. The company reported ($0.25) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.09) by ($0.16).

A hedge fund recently bought a new stake in Kintara Therapeutics stock. IPG Investment Advisors LLC purchased a new position in Kintara Therapeutics, Inc. (NASDAQ:KTRA) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 26,000 shares of the company’s stock, valued at approximately $36,000. IPG Investment Advisors LLC owned 0.11% of Kintara Therapeutics at the end of the most recent reporting period. 2.14% of the stock is currently owned by hedge funds and other institutional investors.

About Kintara Therapeutics

Kintara Therapeutics, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer.

Featured Story: Float

Earnings History and Estimates for Kintara Therapeutics (NASDAQ:KTRA)

Receive News & Ratings for Kintara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kintara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.